Primary ocular adnexal double-expression diffuse large B-cell lymphoma treated with R-MAD regimen: report of one case and review of literature
10.3760/cma.j.cn115356-20191104-00214
- VernacularTitle:R-MAD方案治疗原发眼附属器双表达弥漫大B细胞淋巴瘤一例并文献复习
- Author:
Yanquan LIU
1
;
Jianzhen SHEN
;
Haiying FU
;
Huarong ZHOU
;
Langhui ZHANG
;
Weili ZHENG
Author Information
1. 福建医科大学附属协和医院血液内科,福州 350001
- From:
Journal of Leukemia & Lymphoma
2020;29(4):240-243
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical effect of R-MAD (rituximab, methotrexate, cytarabine, dexamethasone) regimen in the treatment of primary ocular adnexal double-expression diffuse large B-cell lymphoma (DLBCL).Methods:The clinical data of an elderly patient with primary ocular adnexal double-expression DLBCL who was treated with R-MAD regimen in June 2019 in Fujian Medical University Union Hospital was retrospectively analyzed. The clinical manifestations, diagnosis and treatment, prognosis were also analyzed, and the related literature was reviewed.Results:The patients was a 71-year-old male. After initial treatment of R-CHOP chemotherapy, the patient's eye mass did not shrink, the swelling and pain became worse, the curative effect was not good, and the disease progression continued. After the patient was given R-MAD chemotherapy for 3 courses, the eye swelling subsided and pain symptoms were significantly improved, satisfactory results were obtained, and no obvious adverse reactions occurred.Conclusions:R-MAD regimen has an ideal effect on the patient with primary ocular adnexal double-expression DLBCL, which can significantly improve symptoms, delay disease progression, and improve the quality of life of patients, but the prognosis still needs to be followed up in the long-term.